ECOR
NASDAQelectroCore Inc.
Price$7.99+0.07 (+0.82%)
06:15 PM07:45 PM
News · 26 weeks44-93%
2026-04-192026-10-11
Mix2390d
- Insider13(57%)
- SEC Filings4(17%)
- Other4(17%)
- Earnings1(4%)
- Leadership1(4%)
Latest news
25 items- INSIDERDirector Errico Thomas J. bought $49,082 worth of shares (5,000 units at $9.82), increasing direct ownership by 1% to 363,904 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERAmendment: Officer Fox Michael bought $49,004 worth of shares (5,000 units at $9.80), increasing direct ownership by 4% to 130,000 units (SEC Form 4)4/A - electroCore, Inc. (0001560258) (Issuer)
- INSIDEROfficer Fox Michael was granted 5,000 shares, increasing direct ownership by 4% to 130,000 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Theofilos James Charles was granted 11,123 shares, increasing direct ownership by 47% to 34,670 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Goldstein Julie Ann was granted 11,123 shares, increasing direct ownership by 11% to 112,510 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Wilber Patricia was granted 11,123 shares, increasing direct ownership by 15% to 83,448 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Errico Thomas J. was granted 15,572 shares, increasing direct ownership by 5% to 358,904 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Bonfiglioli Elena was granted 11,123 shares, increasing direct ownership by 36% to 41,672 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDEROfficer Fox Michael was granted 55,000 shares, increasing direct ownership by 79% to 125,000 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDEROfficer Lev Joshua S. was granted 55,000 shares, increasing direct ownership by 65% to 139,889 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- INSIDERDirector Gandolfo John P was granted 11,123 shares, increasing direct ownership by 13% to 99,221 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- PRelectroCore to Participate at H.C. Wainwright Global Investment ConferenceROCKAWAY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the H.C. Wainwright 28th Annual Global Investment Conference at the Lotte New York Palace Hotel. On Tuesday, September 15, 2026, Joshua Lev, Co-CEO, President and CFO, will participate in a fireside chat and host one-on-one meetings with investors during the conference. Investors who wish to request a meeting should contact their sales representative at H.C. Wainwright or reach out to electroCore Investor Relations at investors@electrocore.com. About electroCore, Inc.electroCore, Inc. is a
- SECelectroCore Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Financial Statements and Exhibits8-K - electroCore, Inc. (0001560258) (Filer)
- PRelectroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive OfficersROCKAWAY, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced that it has appointed Joshua Lev and Mike Fox as Co-Chief Executive Officers and members of the Board of Directors, effective September 8, 2026. Following a deliberate leadership and succession process, it became clear that both Joshua and Mike possess the judgment, experience, vision, and leadership capabilities required of a Chief Executive Officer. The Company concluded that its strongest path forward was to bring their distinct and complementary strengths toget
- INSIDERCFO and Interim President Lev Joshua S. exercised 20,000 shares at a strike of $4.50 and sold $200,120 worth of shares (20,000 units at $10.01) (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- PRelectroCore’s Truvaga® Named Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle AwardsROCKAWAY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a bioelectronic technology company, today announced that Truvaga, its non-invasive vagus nerve stimulation (nVNS) wellness brand, has been named the 2026 Best Luxury Biohacking & Longevity Brand in the USA by Luxury Lifestyle Awards. The award recognizes Truvaga for bringing together scientific innovation, patented technology, thoughtful product design and a high-touch customer experience to make nervous system wellness more accessible for everyday use. Truvaga offers handheld, non-invasive vagus nerve stimulation devices intended to support relaxation, stress management, sleep quality, focus and overall we
- INSIDERDirector Errico Thomas J. bought $49,272 worth of shares (5,000 units at $9.85), increasing direct ownership by 1% to 343,332 units (SEC Form 4)4 - electroCore, Inc. (0001560258) (Issuer)
- SECSEC Form 10-Q filed by electroCore Inc.10-Q - electroCore, Inc. (0001560258) (Filer)
- SECelectroCore Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - electroCore, Inc. (0001560258) (Filer)
- PRelectroCore Announces Second Quarter 2026 Financial ResultsSecond quarter 2026 net sales of $9.5 million, an increase of 28% over $7.4 million in the second quarter 2025 Net loss of $3.1 million decreased 17% from prior year with Adjusted EBITDA net loss improving 26% from prior-year period Increasing 2026 revenue guidance to greater than 30% year-over-year growth Company to host a conference call and webcast today, August 6, 2026, at 4:30 pm EDT ROCKAWAY, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR) ("electroCore" or the "Company"), a bioelectronic technology company, today announced financial results for the second quarter ended June 30, 2026. The Company reported quarterly revenue of $9.5 million, an increase of
- PRelectroCore to Participate in Upcoming Investor ConferencesROCKAWAY, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the following investor conferences: Needham 11th Annual Virtual MedTech and Diagnostics Conference, taking place virtually on Tuesday, August 11, 2026. Management will host one-on-one meetings virtually.Canaccord Genuity 46th Annual Growth Conference, taking place in Boston, Massachusetts, on Tuesday, August 11, and Wednesday, August 12, 2026, at the InterContinental Boston. Management will present on Tuesday, August 11, at 4:30 p.m. ET and will host one-on-one meetings on Wednesday, August 12
- PRelectroCore to Announce Second Quarter June 30, 2026, Financial Results on Thursday, August 6, 2026ROCKAWAY, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the second quarter ended June 30, 2026, after the close of the market on Thursday, August 6, 2026. Management will host a webinar at 4:30 PM EDT to review the financial results and answer questions. Investors can access the webinar using the details below: Thursday, August 6, 4:30 PM EDTDial-In: (646) 931-3860Webinar ID: 849 0856 5421Passcode: 305949Registration Link: Click here to participate and ask questions on the call. About electroCore, Inc.electroCore, Inc. is a bioelectronic te
- SECSEC Form DEF 14A filed by electroCore Inc.DEF 14A - electroCore, Inc. (0001560258) (Filer)
- PRNew Review Examines Anatomical and Methodological Differences Between Auricular and Cervical Vagus Nerve StimulationROCKAWAY, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company and leader in non-invasive vagus nerve stimulation technologies, today announced the publication of the peer-reviewed review article, "Two Paths to the Body's Superhighway—The Auricular Branch (taVNS) and the Cervical Bundle (tcVNS): A Narrative Review," in Frontiers in Neuroscience. The article was authored by Peter S. Staats, MD, MBA, Chief Medical Officer of electroCore, and Justyna Blake, Senior Director of Medical Affairs at electroCore. The review examines the two primary approaches to transcutaneous vagus nerve stimulation (tVNS): transcu
- PRelectroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment ConferenceROCKAWAY, N.J., June 17, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. Joshua Lev, Interim President and Chief Financial Officer, will deliver a presentation and host one-on-one investor meetings during the conference. iAccess Alpha Virtual Best Ideas Summer Investment Conference Dates: June 23-24, 2026Presentation Time: Tuesday, June 23 at 1:30 p.m. ETWebcast: https://www.webcaster5.com/Webcast/Page/3165/54084 For more information about the iAccess Alpha Virtual Best Ideas Summer In
ECOR FAQ
7 questionsWhat does electroCore Inc. do?
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in Rockaway, New Jersey.Where does ECOR stock trade?
electroCore Inc. (ECOR) is listed on NASDAQ.What sector and industry is ECOR in?
electroCore Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did electroCore Inc. go public?
electroCore Inc. (ECOR) completed its IPO in 2018.What are analysts saying about ECOR?
electroCore Inc. has had 2 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy with a $275.00 price target on 2022-01-19. Recent price targets range from $275.00 to $300.00.What companies are similar to ECOR?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare ECOR side-by-side with any of them on Quantisnow.How can I track ECOR on Quantisnow?
Quantisnow aggregates electroCore Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ECOR to receive live email and push alerts on every new disclosure.